ANTHEM
Anthem Biosciences Limited (ANTHEM) Stock Analysis
Anthem Biosciences Limited is an Indian biologics and biosimilars contract research and manufacturing company. It provides development and manufacturing services for large-molecule drugs to global pharma clients. The company is part of India's growing biologics CDMO sector. It is a recently listed healthcare services company.
Healthcare › Biotechnology
₹847.80
-4.43% 1W | +12.20% 52W
Market Cap
47.6k CR
P/E Ratio
83.5
52W High
₹977.5
52W Low
₹579.1
Div. Yield
0.23%
Beta
–
50 DMA
₹893.3
200 DMA
₹760.4
Profit Margin
28.7%
Inst. Own.
12.9%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 |
| OPM % | 36% | 37% | 32% | 40% | 35% | 40% | 37% | 44% | 36% |
| Other Income | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 |
| Profit before tax | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 |
| Tax % | 30% | 19% | 23% | 54% | 27% | 24% | 29% | 32% | 17% |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 |
| EPS in Rs | 1.47 | 2.90 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 | 2.13 |
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | 2,124 | 2,002 |
| Expenses | 451 | 695 | 666 | 626 | 914 | 1,173 | 1,290 | 1,209 |
| Operating Profit | 182 | 408 | 565 | 431 | 506 | 672 | 834 | 793 |
| OPM % | 29% | 37% | 46% | 41% | 36% | 36% | 39% | 40% |
| Other Income | 21 | 37 | 49 | 139 | 63 | 85 | 131 | 133 |
| Interest | 20 | 17 | 10 | 9 | 10 | 11 | 7 | 6 |
| Depreciation | 62 | 62 | 58 | 64 | 82 | 89 | 134 | 138 |
| Profit before tax | 121 | 366 | 546 | 497 | 477 | 657 | 824 | 783 |
| Tax % | 23% | 26% | 26% | 23% | 23% | 31% | 28% | |
| Net Profit | 93 | 271 | 406 | 385 | 367 | 451 | 592 | 576 |
| EPS in Rs | 110.62 | 319.74 | 462.09 | 6.75 | 6.57 | 8.07 | 10.54 | 10.25 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 19% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 26.0% | 14.0% | – |
| Profit CAGR | 21.0% | 17.0% | – |
Shareholding Pattern
Promoters74.69%
FIIs1.66%
DIIs7.21%
Public16.42%
Promoters74.69%
FIIs1.37%
DIIs7.60%
Public16.34%
Promoters74.67%
FIIs1.28%
DIIs11.55%
Public12.48%
Promoters71.42%
FIIs2.57%
DIIs13.48%
Public12.52%
Promoters74.67%
FIIs1.28%
DIIs11.55%
Public12.48%
Promoters71.42%
FIIs2.57%
DIIs13.48%
Public12.52%
ANTHEM
Holdings Analysis
Key strengths & risk signals
74
Overall
76
Fundamental
72
Technical
Risks (3)
OVERVALUED! PEG of 5.70 means expensive relative to growth rate.
RECOVERY MODE! Current price (870.1) above 200-day but below 50-day.
WEAK MOMENTUM! Limited price growth - -2.3% (1 week), -7.5% (1 month), 15.9% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (891.2) is above 200-day average (758.1) - positive signal.
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 1,187,185 vs down days: 566,312. Ratio: 2.1x
UPPER HALF! Trading at 73.0% of 52W range - positive territory.
Fundamental & Technical Analysis
74Overall
76Fundamental
72Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 26.2% (EXCELLENT, 15/15). Profit CAGR: 15.4% (VERY GOOD, 13/15).
Profit Margin
9/10
EXCELLENT EFFICIENCY! 28.7% profit margin - company keeps strong profits.
PEG Valuation
0/10
OVERVALUED! PEG of 5.42 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.23% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
16/20
LESS PUBLIC HOLDING! 16.42% public ownership - good institutional/promoter control.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (893.3) is above 200-day average (760.4) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (847.8) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
6/10
POSITIVE YEAR! Stock gained 12.2% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 11 up days, 19 down days. Avg volume on up days: 1,187,185 vs down days: 532,817. Ratio: 2.23x
RSI
3/5
NEUTRAL! RSI at 41.4 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 67.4% of 52W range - positive territory.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -4.4% (1 week), -9.9% (1 month), 11.7% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
ANTHEM
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-07-27 | Concall PDF | |
| Q3FY262026-02-09 | Concall PDF | |
| Q2FY262025-11-12 | Concall PDF |
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTHEM | ₹847.80 | 83.5 | 28.7% | 26.2% | 15.4% | +12.2% | 74 | BREAKDOWN | -11.7% | -36.8% | -22.6% | -31.5% |
| BIOCON | ₹350.60 | 103.7 | 2.9% | 15.3% | -5.9% | -2.8% | 62 | BOUNCE FROM SUPPORT | +349.4% | +12.1% | +9.8% | -4.3% |
| ONESOURCE | ₹1,442.40 | – | -3.1% | 232.4% | – | -20.4% | 44 | BREAKDOWN | -12,600.0% | +443.5% | +37.2% | +4.9% |
| CONCORDBIO | ₹1,382.10 | 48.1 | 24.8% | 8.0% | 2.8% | -10.2% | 56 | BREAKDOWN | +30.8% | -35.0% | +26.2% | -21.0% |
| BLUEJET | ₹522.50 | 38.6 | 26.5% | 9.4% | 15.7% | -21.6% | 69 | BREAKDOWN | -14.1% | +21.8% | -17.4% | +24.9% |
| SUPRIYA | ₹874.50 | 35.5 | 22.7% | 21.2% | 32.5% | +22.4% | 81 | BREAKDOWN | -31.0% | -67.7% | +30.7% | -31.4% |
| ZOTA | ₹1,420.10 | – | -17.0% | 56.7% | – | -13.6% | 54 | APPROACHING RESISTANCE | +204.9% | +207.0% | +67.6% | +6.4% |
| DCAL | ₹153.00 | 148.6 | 0.6% | 9.0% | 21.0% | -48.1% | 50 | APPROACHING RESISTANCE | -347.9% | -367.3% | -4.2% | -20.4% |
Data from TradeAlone · Updated daily
ANTHEM News
Anthem Biosciences Limited (NSE: ANTHEM) breaks out, gains 5% intraday2026-08-11Anthem Biosciences Limited (NSE: ANTHEM) breaks below support, falls 5%2026-07-22Anthem Biosciences Limited Announces Investor Presentation on July 21, 20262026-07-21Anthem Biosciences Limited (NSE: Anthem) Investor Presentation July 21, 2026: Strong Business Performance and Robust Margins2026-07-21Anthem Biosciences Limited (NSE: Anthem) Q4 FY26: Revenue Up 26%, PAT Surges 130%2026-05-19
